Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kedia, S.
Right arrow Articles by Kumar, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kedia, S.
Right arrow Articles by Kumar, R.
Related Collections
Right arrow Parkinson's disease/Parkinsonism
Right arrow Restless legs syndrome
Right arrow Surgery/Stimulation
NEUROLOGY 2004;63:2410-2412
© 2004 American Academy of Neurology
Brief Communications

Emergence of restless legs syndrome during subthalamic stimulation for Parkinson disease

S. Kedia, BA, E. Moro, MD, PhD, M. Tagliati, MD, A. E. Lang, MD and R. Kumar, MD

From the University of Colorado Health Sciences Center (S. Kedia), Denver, and Colorado Neurological Institute (Dr. Kumar), Englewood, CO, and Beth Israel Medical Center (Dr. Tagliati), New York, NY, and Movement Disorders Center (Drs. Moro and Lang), University Health Network, Toronto, Ontario, Canada.

Address correspondence and reprint requests to Dr. R. Kumar, Colorado Neurological Institute, 1443 S. St. Paul St., Denver, CO 80201; e-mail: rajeev_kumar{at}msn.com

The authors systematically studied the emergence of restless legs syndrome (RLS) after subthalamic nucleus (STN) deep brain stimulation (DBS) for Parkinson disease (PD). Postoperatively, 11 of 195 patients with STN DBS reported new problematic symptoms of RLS. The mean reduction in antiparkinsonian medication was 74%. The mean RLS score at diagnosis was 15 (±5.9) of a possible 24 points and after symptomatic drug therapy 4.3 (±3.1) points. Reduction of antiparkinsonian medication during STN DBS may unmask symptoms of RLS and complicate therapy of both RLS and PD.

Received April 14, 2004. Accepted in final form August 2, 2004.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by AAN Enterprises, Inc.